{"nctId":"NCT00116831","briefTitle":"Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes","startDateStruct":{"date":"2005-01"},"conditions":["Atherosclerosis"],"count":672,"armGroups":[{"label":"Glipizide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glipizide"]},{"label":"rosiglitazone maleate","type":"EXPERIMENTAL","interventionNames":["Drug: rosiglitazone maleate"]}],"interventions":[{"name":"Glipizide","otherNames":[]},{"name":"rosiglitazone maleate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Male or female between 30 to 80 years of age, inclusive.\n* Established diagnosis of T2DM (based on diagnostic criteria of the American Diabetes Association (ADA), WHO guidelines or local national guidelines).\n* Subjects who are undergoing coronary angiography for evaluation of suspected or previously diagnosed coronary artery disease or who are undergoing PCI.\n* Subjects' prior anti-hyperglycemic diabetic therapy:\n\nDiet and exercise only (drug naïve), with HbA1c \\>7.0 and £ 10.0%. HbA1c \\> 6.5 and \\<= 8.5%.\n\n* Left ventricular ejection fraction (EF) ³ 40% as assessed by contrast ventriculography (or previously documented in medical notes within one month prior to index procedure by other methods e.g. echocardiography or nuclear study)\n* Female subjects must be postmenopausal (i.e., \\>6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant, Depo-Provera, an intra-uterine device (IUD), a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1a, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.\n* Willingness and ability to give informed consent prior to entering the study and available to complete the study.\n\nExclusion Criteria:\n\n* Type 1 diabetes and/or history of diabetic ketoacidosis.\n* Exposure to a TZD or other PPAR-g agonist within the 6 months prior to screening visit.\n* Subjects treated with triple OAD therapy or high dose dual combination OAD therapy \\[1\\].\n* Subjects who have required chronic insulin use in the last 6 months (except during pregnancy or acute episodes such as hospitalization, trauma or infection).\n* ST segment elevation myocardial infarction in the last 30 days.\n* Subjects who have a history or are scheduled to receive coronary artery bypass graft surgery (CABG), valve repair or replacement, aneurysmectomy or planned major non-cardiac surgery during the study period.\n* Subjects who have severe cardiac valvular disease\n* Stroke or resuscitated in the past 6 months\n* History of congestive heart failure (NYHA class I - IV)\n* History of significant hypersensitivity or reaction (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to any TZD, SU, biguanide or insulin\n* Prior history of severe edema or edema requiring medical treatment.\n* Chronic disease requiring chronic or intermittent treatment with oral, intravenous, or injected corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).\n* Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months.\n* Untreated hypo- or hyperthyroidism\n* A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer.\n* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgement of the Investigator, would preclude safe completion of the study.\n* Blood pressure: SBP \\>170 or DBP \\> 100 mmHg\n* Significant anemia (Hemoglobin \\< 11 g/dL for males and \\< 10 g/dL for females).\n* Significant renal disease manifested by serum creatinine (\\> 1.5mg/dL for males or \\> 1.4mg/dL for females), or where the use of metformin is contra-indicated.\n* Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \\> 2.5 times upper limit of normal (ULN) or bilirubin \\>2x ULN).\n* History of myopathy or history of elevated creatine kinase (CK) \\> 3 times upper normal limit.\n* Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer).\n* Women who are lactating, pregnant or planning to become pregnant during the course of the study.\n* Unwillingness or inability to comply with the procedures described in this protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in Atheroma, Vessel, and Lumen Volume to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"249.747","spread":"150.4095"},{"groupId":"OG001","value":"222.431","spread":"137.4193"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249.625","spread":"149.7098"},{"groupId":"OG001","value":"218.576","spread":"134.3462"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.123","spread":"28.1627"},{"groupId":"OG001","value":"-3.854","spread":"25.8846"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"609.378","spread":"311.7587"},{"groupId":"OG001","value":"555.062","spread":"297.9848"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"603.088","spread":"304.3434"},{"groupId":"OG001","value":"547.186","spread":"298.2100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.290","spread":"52.7032"},{"groupId":"OG001","value":"-7.876","spread":"40.4948"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"359.726","spread":"195.6810"},{"groupId":"OG001","value":"332.688","spread":"192.3850"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"353.513","spread":"192.2419"},{"groupId":"OG001","value":"328.676","spread":"191.9313"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.213","spread":"56.0042"},{"groupId":"OG001","value":"-4.012","spread":"38.5260"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change From Baseline in Atheroma Volume to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"2.001"},{"groupId":"OG001","value":"-3.60","spread":"2.002"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change From Baseline in Lumen Volume to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.91","spread":"3.545"},{"groupId":"OG001","value":"-4.59","spread":"3.526"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change From Baseline in Vessel Volume to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.56","spread":"3.479"},{"groupId":"OG001","value":"-8.13","spread":"3.466"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Atheroma, Vessel, and Lumen Area to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.918","spread":"2.9281"},{"groupId":"OG001","value":"5.748","spread":"2.5585"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.928","spread":"2.9615"},{"groupId":"OG001","value":"5.634","spread":"2.5594"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.010","spread":"0.6448"},{"groupId":"OG001","value":"-0.114","spread":"0.6990"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.364","spread":"5.1946"},{"groupId":"OG001","value":"14.166","spread":"4.8231"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.261","spread":"5.1699"},{"groupId":"OG001","value":"13.977","spread":"4.8595"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.102","spread":"1.1954"},{"groupId":"OG001","value":"-0.189","spread":"0.9918"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.447","spread":"3.2037"},{"groupId":"OG001","value":"8.419","spread":"3.2847"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.335","spread":"3.2056"},{"groupId":"OG001","value":"8.344","spread":"3.3077"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.113","spread":"1.2166"},{"groupId":"OG001","value":"-0.075","spread":"0.9207"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change From Baseline in Atheroma Area to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.050"},{"groupId":"OG001","value":"-0.10","spread":"0.050"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change From Baseline in Lumen Area to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.079"},{"groupId":"OG001","value":"-0.11","spread":"0.079"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change From Baseline in Vessel Area to Month 18","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.10","spread":"0.082"},{"groupId":"OG001","value":"-0.21","spread":"0.082"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Normalized Atheroma Volume","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Normalized atheroma volume is defined as mean atheroma area x median segment length in cohort.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232.772","spread":"115.1630"},{"groupId":"OG001","value":"226.075","spread":"100.6261"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233.153","spread":"116.4765"},{"groupId":"OG001","value":"221.599","spread":"100.6606"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.381","spread":"25.3600"},{"groupId":"OG001","value":"-4.476","spread":"27.4901"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Percent Atheroma Volume (PAV) to Month 18","description":"The primary efficacy endpoint was change in PAV (defined as total atheroma volume divided by total vessel volume x 100) within a 40 mm segment in non-intervened coronary arteries from Baseline to Month 18, based upon Intravascular Ultrasound (IVUS) assessment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.593","spread":"10.9717"},{"groupId":"OG001","value":"40.422","spread":"11.7506"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.013","spread":"11.1572"},{"groupId":"OG001","value":"40.182","spread":"11.4257"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.420","spread":"4.8085"},{"groupId":"OG001","value":"-0.240","spread":"4.2421"}]}]}]},{"type":"PRIMARY","title":"Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18","description":"Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior Oral Anti-Hyperglycemic Diabetic Medications(s) (OAD).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.331"},{"groupId":"OG001","value":"-0.21","spread":"0.331"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change From Baseline in Normalized Atheroma Volume","description":"IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Normalized atheroma volume is defined as mean atheroma area x median segment length in cohort. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"1.974"},{"groupId":"OG001","value":"-3.92","spread":"1.983"}]}]}]},{"type":"SECONDARY","title":"Change in Atheroma Volume Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline","description":"IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.649","spread":"32.6125"},{"groupId":"OG001","value":"70.961","spread":"29.9610"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.225","spread":"33.2887"},{"groupId":"OG001","value":"66.020","spread":"30.7228"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.424","spread":"11.9263"},{"groupId":"OG001","value":"-4.941","spread":"12.2005"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change in Atheroma Volume Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline","description":"IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.56","spread":"0.892"},{"groupId":"OG001","value":"-5.28","spread":"0.898"}]}]}]},{"type":"SECONDARY","title":"Change in Atheroma Area Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline","description":"IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.569","spread":"3.2718"},{"groupId":"OG001","value":"7.093","spread":"3.0042"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.185","spread":"3.2957"},{"groupId":"OG001","value":"6.625","spread":"3.0741"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.384","spread":"1.0608"},{"groupId":"OG001","value":"-0.468","spread":"1.1370"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change in Atheroma Area Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline","description":"IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"0.081"},{"groupId":"OG001","value":"-0.50","spread":"0.082"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change in Glycated Hemoglobin (HbA1c) From Baseline to Month 18","description":"From repeated measures analysis model: Change = Baseline + visit + sex + region + treatment + prior Oral Anti-Hyperglycemic Diabetic Medications(s) (OAD) + cardiac procedure + treatment x visit.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.051"},{"groupId":"OG001","value":"-0.30","spread":"0.053"}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Change in Fasting Plasma Glucose (FPG) From Baseline to Month 18","description":"From repeated measures analysis model: Change = Baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"0.138"},{"groupId":"OG001","value":"-1.34","spread":"0.145"}]}]}]},{"type":"SECONDARY","title":"Repeated Measures Analysis of Percent Change in hsCRP From Baseline to Month 18","description":"Changes in cardiovascular biomarkers from Baseline to Month 18, such as high sensitivity C-reactive protein (hsCRP) . Repeated measures analysis model: Log(value) - log(baseline) = log(baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.82","spread":"-67.40"},{"groupId":"OG001","value":"-80.33","spread":"-82.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-65.18","spread":null},{"groupId":"OG001","value":"-81.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.40","spread":null},{"groupId":"OG001","value":"-82.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Repeated Measures Analysis of Percent Change in MMP 9 From Baseline to Month 18","description":"Changes in cardiovascular biomarkers from Baseline to Month 18, such as matrix metalloproteinase-9 (MMP-9). Repeated measures analysis model: Log(value) - log(baseline) = log(baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.5","spread":"-34.3"},{"groupId":"OG001","value":"-38.8","spread":"-45.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.5","spread":null},{"groupId":"OG001","value":"-42.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.3","spread":null},{"groupId":"OG001","value":"-45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Brain Natriuretic Peptide (BNP) From Baseline to Month 18","description":"It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1)It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1). Ratio to baseline as %change mean (%) was used as the estimation parameter for both groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.141","spread":"-13.764"},{"groupId":"OG001","value":"30.189","spread":"11.683"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.608","spread":null},{"groupId":"OG001","value":"20.582","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.764","spread":null},{"groupId":"OG001","value":"11.683","spread":null}]}]}]},{"type":"SECONDARY","title":"Model Adjusted Percent Change in Brain Natriuretic Peptide (BNP) From Baseline to Month 18","description":"It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1). Model Adjusted change based on ANCOVA: Log(value) - log(Baseline) = log(Baseline) + sex + region + treatment + prior OAD + cardiac procedure.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.865","spread":"-17.465"},{"groupId":"OG001","value":"24.576","spread":"7.499"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.388","spread":null},{"groupId":"OG001","value":"15.720","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.465","spread":null},{"groupId":"OG001","value":"7.499","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in Total Cholesterol (TC)","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.205","spread":null},{"groupId":"OG001","value":"3.151","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.644","spread":null},{"groupId":"OG001","value":"1.567","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.062","spread":null},{"groupId":"OG001","value":"0.007","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in High Density Lipoprotein Cholesterol (HDL-c)","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.208","spread":null},{"groupId":"OG001","value":"15.104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.710","spread":null},{"groupId":"OG001","value":"13.440","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.233","spread":null},{"groupId":"OG001","value":"11.808","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in HDL-2","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.065","spread":null},{"groupId":"OG001","value":"18.241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.783","spread":null},{"groupId":"OG001","value":"14.821","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.550","spread":null},{"groupId":"OG001","value":"11.507","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in HDL-3","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.683","spread":null},{"groupId":"OG001","value":"15.165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.074","spread":null},{"groupId":"OG001","value":"13.440","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.490","spread":null},{"groupId":"OG001","value":"11.732","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in Low Density Lipoprotein Cholesterol (LDL-c)","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.955","spread":null},{"groupId":"OG001","value":"1.795","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.600","spread":null},{"groupId":"OG001","value":"-1.237","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.172","spread":null},{"groupId":"OG001","value":"-4.180","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in Triglycerides (TG)","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.415","spread":null},{"groupId":"OG001","value":"-13.601","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.309","spread":null},{"groupId":"OG001","value":"-16.381","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.110","spread":null},{"groupId":"OG001","value":"-19.067","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in Free Fatty Acids (FFA)","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.909","spread":null},{"groupId":"OG001","value":"13.835","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.303","spread":null},{"groupId":"OG001","value":"8.880","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.943","spread":null},{"groupId":"OG001","value":"4.142","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Month 18 in Apoprotein B (apoB)","description":"Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.588","spread":"-10.021"},{"groupId":"OG001","value":"-6.967","spread":"-10.488"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.320","spread":null},{"groupId":"OG001","value":"-8.744","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.021","spread":null},{"groupId":"OG001","value":"-10.488","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 18 in LDL-c Peak Particle Density Measured by LDL Relative Flotation","description":"From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0040","spread":"0.00158"},{"groupId":"OG001","value":"0.0204","spread":"0.001630"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 18 in Total Cholesterol/HDL-c Ratio","description":"From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.495","spread":"0.08380"},{"groupId":"OG001","value":"-0.377","spread":"0.08620"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 18 in LDL-c/HDL-c Ratio","description":"From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.365","spread":"0.0610"},{"groupId":"OG001","value":"-0.226","spread":"0.0629"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for All-cause Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularization, or Hospitalization for Recurrent Myocardial Ischemia (MACE Composite 1)","description":"This was 1 of 2 MACE composite endpoints and was a secondary efficacy endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke (MACE Composite 2)","description":"This was 1 of 2 MACE composite endpoints and was a secondary efficacy endpoint.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Other Cardiovascular Events","description":"This was one of the secondary endpoints of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":337},"commonTop":["Angina pectoris","Edema peripheral","Hypertension","Cough","Dizziness"]}}}